US OptionsDetailed Quotes
ATHA241115P7500
- 0.00
- 0.000.00%
15min DelayTrading Oct 31 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover0.00%IV-1620.18%PremiumNov 15, 2024Expiry Date7.06Intrinsic Value100Multiplier15DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.05Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Athira Stock Discussion
that's alot of extra cash
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases
Athira Pharma (NASDAQ: ATHA) announced a strategic shift to focus on advancing ATH-1105, an oral, next-generation small molecule positive modulator of the HGF system, for treating neurodegenerative diseases like ALS and Alzheimer's. This decision follows the topline data readout from the Phase 2/3 LIFT-AD trial of fosgonimeton. The company is implementing cost containment meas...
No comment yet